MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...
SGLT2i and GLP-1RA are associated with lower risks of hyperkalemia compared with DPP4i in patients with CKD and type 2 diabetes. Hyperkalemia risks in patients with chronic kidney disease (CKD) and ...
SGLT2 inhibitors offer significant benefits in CKD and HF, yet remain underutilized in primary care settings. An interprofessional initiative developed a prescription algorithm to enhance SGLT2 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors cut the risk for adverse CV outcomes ...
New data from the landmark FLOW trial, which linked the glucagon peptide 1 (GLP-1) receptor agonist semaglutide with significant kidney outcomes in patients with type 2 diabetes (T2D) and chronic ...
SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...
Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...
Use of SGLT2 inhibitors rather than GLP-1 receptor agonists is associated with lower risk of progression to kidney replacement therapy among patients with type 2 diabetes and CKD. The risk of ...
When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...
Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may confer similar kidney and CV outcomes vs. GLP-1 receptor agonists for diabetes. Results ...
Hosted on MSN
How Quickly Does Farxiga Cause Weight Loss?
Farxiga (dapagliflozin) is an orally administered, brand-name medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 inhibitors help lower blood sugar by causing the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback